Meeting
2016 Genitourinary Cancers Symposium
The risk-based STHLM3 model to improve prostate cancer testing in men 50-69 years: Further health, economic, and clinic evaluation.
Authors
Henrik Gronberg
Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden
Henrik Gronberg , Jan Adolfsson , Markus Aly , Tobias Nordström , Peter Wiklund , Yvonne Brandberg , James Thompson , Fredrik Wiklund , Johan Lindberg , Mark Clements , Lars Egevad , Martin Eklund
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Clinical Trial Registration Number
ISRCTN84445406
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 36)
DOI
10.1200/jco.2016.34.2_suppl.36
Abstract #
36
Poster Bd #
B18
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Methylated DNA markers in urine aid in the selective identification of patients with prostate cancer as well as clinically significant pathology.
First Author: Paras Shah
Poster
2016 Genitourinary Cancers Symposium
The change in prostate cancer presentation and diagnosis coinciding with screening recommendations.
First Author: Franklin Gaylis
Poster
2014 Genitourinary Cancers Symposium
Association of PTEN protein loss with upgrading of prostate cancer from biopsy to radical prostatectomy.
First Author: Filipe LF Carvalho
Poster
2024 ASCO Genitourinary Cancers Symposium
Exploring the utility of prostate-derived extracellular vesicles as a urine biomarker for clinically significant prostate cancer.
First Author: Ekamjit Singh Deol